A major US project aimed at finding improved treatments for children with relapsed acute leukaemia is being extended into Europe.
The US-based Leukemia and Lymphoma Society have developed the LLS PedAL clinical trial, with the aim of testing targeted therapies for high-risk leukaemias. It forms part of a $100 million initiative by the charity to tackle children’s cancers.
Earlier this month, the chairs of the LLS PedAL trial set out their plans at the 8th ACCELERATE Paediatric Oncology conference in Brussels.
Professor Christian Michel Zwaan, of Princes Maxima Hospital in Utrecht, Netherlands, and Dr Dirk Reinhart, director of paediatric oncology at the University Hospital in Essen, Germany, are working with the charity on the European end of the project. They are forming a European AML consortium, to ensure as many children from Europe as possible have access to the trial when it launches later this year.
The Leukemia and Lymphoma Society says: “This trial, which will test targeted therapies in children with acute myeloid leukaemia, and eventually other high-risk leukaemias, will benefit not only children in the United States, but in several European countries, as well as the UK, Australia, New Zealand and Canada.
“We anticipate opening the trial in approximately 200 sites around the US, Canada and across the globe.”
Source: Leukemia and Lymphoma Society
Disclaimer: The news stories shared on this site are used as a way to inform our members and followers of updates and relevant information happening in Haematology. The BSH does not endorse the content of news items from external sources, and is not in a position to verify the findings, accuracy or the source of any studies mentioned. Any medical or drugs information is provided as an information resource only, and is not to be relied on for any diagnostic or treatment purposes.
News service provided by Englemed News http://www.englemed.co.uk/